Persista Bio Inc
Publicly observedIthaca, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Ithaca | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Persista Bio Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VSKTVBS3CBW1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant11 Sept 2025Publicly observed
NIH SBIR/STTR award: Manufacturing Clinical-Grade Cell Capsule of O2Line(TM) Implant System for T1D
USD 287,250.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant8 Sept 2025Publicly observed
NIH SBIR/STTR award: Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy
USD 1,006,033.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant8 Sept 2025Publicly observed
NIH SBIR/STTR award: Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy
USD 1,093,967.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.